公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies | Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; CHIA-CHI LIN ; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. | Investigational New Drugs | 15 | 14 | |
2018 | Position paper for the organization of ECMO programs for cardiac failure in adults | Abrams D.; Garan A.R.; Abdelbary A.; Bacchetta M.; Bartlett R.H.; Beck J.; Belohlavek J.; YIH-SHARNG CHEN ; Fan E.; Ferguson N.D.; Fowles J.-A.; Fraser J.; Gong M.; Hassan I.F.; Hodgson C.; Hou X.; Hryniewicz K.; Ichiba S.; Jakobleff W.A.; Lorusso R.; MacLaren G.; McGuinness S.; Mueller T.; Park P.K.; Peek G.; Pellegrino V.; Price S.; Rosenzweig E.B.; Sakamoto T.; Salazar L.; Schmidt M.; Slutsky A.S.; Spaulding C.; Takayama H.; Takeda K.; Vuylsteke A.; Combes A.; Brodie D.; for The International ECMO Network (ECMONet) and The Extracorporeal Life Support Organization (ELSO) | Intensive Care Medicine | 219 | 184 |